WiseTech Global Ltd (ASX:WTC) shares have been one of the most painful holdings on the ASX over the past year.

The logistics software company was once an undisputed market darling. Today, it is a battleground stock.

So when will WiseTech shares finally bottom out?

Let’s dig in.

Why WiseTech shares have crashed

The damage for ASX investors has been severe.

WiseTech shares are down roughly 50% in 2026 and around 70% over the past 12 months.

They remain a long way below their 52-week high of $121.31.

Curiously, the problem is not the underlying business, as demand for WiseTech’s CargoWise platform remains solid. As a result, the company is still profitable and still growing.

The real issue is governance.

Investors grew uneasy about scrutiny surrounding founder Richard White. Recent reports have emerged of an Australian Federal Police investigation into White. The allegations centre on claims that he exploited a woman’s immigration and financial situation and provided false information on a visa application.

The complaint reportedly came from a former WiseTech cleaner.

Markets can cope with bad news, but what they cannot stand is uncertainty. This uncertainty has weighed heavily on WiseTech shares.

It is also not the first time White has been caught up in scandal. He previously stepped down as CEO after a wave or reports about secret relationshps with women linked to the company. Another scandal involved allegations that he used company shares and company-related arrangements in ways that were not fully transparent.

What could help WiseTech shares bottom out?

A few things would need to fall into place.

First, the company has moved to clean up its governance. White stepped down as Chair, although he remains on the board as an Executive Director. Raelene Murphy has taken over as Independent Chair.

Bell Potter views that appointment as a positive move. The broker has retained a buy rating and $71.75 price target on WiseTech shares, arguing that the stock looks cheap on an FY27 EV/EBITDA multiple of around 15 times.

That compares to roughly 27 times for rival TechnologyOne Ltd (ASX: TNE).

Second, investors want proof in the numbers, and the FY26 full-year result in August looms as a key catalyst.

A solid result with reassuring FY27 guidance could help the shares find a floor. Resolution of the legal matters surrounding White would help, too.

Until then, expect the volatility to continue.

Foolish takeaway

So, when will WiseTech shares bottom out?

Nobody can call the exact low.

The business itself still looks strong, and brokers see substantial upside from here, but sentiment will likely stay volatile until the governance cloud lifts.

For patient investors, the coming FY26 result could be the moment WiseTech shares finally turn a corner.

The post When will WiseTech shares bottom out? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Sigma Healthcare, Wisetech Global, CBA shares
• Why WiseTech shares could rocket 100%
• 5 things to watch on the ASX 200 on Monday
• Are Macquarie, Qantas, and WiseTech shares buys?
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares rose 2.77% and delivered total returns, including dividends, of 7% in FY26.  

Here, we review three fresh buy, hold, and sell calls from expert market analysts.

Weebit Nano Ltd (ASX: WBT)

The Weebit Nano share price soared 414% in FY26 to finish at $8.35 per share.

This was a vastly different performance to many of its peers, which suffered major declines amid a broader tech sector rout. 

Weebit develops advanced semiconductor memory technology.

Mark Elzayed from Investor Pulse reckons there’s more growth ahead for this ASX tech share.

He explains his buy rating on The Bull this week:

Licensing deals with Texas Instruments and onsemi have contributed to company performance. Revenue guidance of $10 million in full year 2026 and a recent capital raising of $102 million fortifies the balance sheet for artificial intelligence and research development.

The shift towards a recurring royalty model generates long term operating leverage.

Momentum and news flow are positive, although the multi year path from licence to royalty income remains the key execution risk.

Metals X Ltd (ASX: MLX)

The Metals X share price ripped 142% to close out FY26 at $1.32.

Elzayed has a hold rating on this ASX materials share.

He explained:

The company is Australia’s largest tin producer. It has a 50 per cent equity interest in the Renison tin operation in Tasmania.

Revenue of $285 million in full year 2025 was up 30 per cent on the prior corresponding period.

However, much of this tin market tightness and consolidation now appears priced into the stock.

The stock is already reflecting a bullish structural tin thesis.

So, in our view, MLX is better suited to holding than buying at these levels.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price fell 29% in FY26 amid a savage healthcare sector downturn. 

However, the stock price of this medical imaging software provider has been recovering strongly since hitting a 52-week low of $107.75 in February.

Pro Medicus shares are up by more than 70% since hitting that floor.

The broader healthcare sector pivoted on 3 June and is also rapidly rising.

Tony Locantro from Alto Capital has a sell recommendation on this ASX 200 healthcare share.

Locantro explained:

The company recently delivered an outstanding first half result in full year 2026. Underlying earnings before interest and tax was up 29.7 per cent and revenue was up 28.4 per cent amid securing more than $A280 million in new contract wins.

Despite these exceptional fundamentals, the company’s premium valuation reflects high market expectations and leaves limited room for disappointment.

While Pro Medicus remains a best-in-class business with strong long term prospects, the current risk-reward balance supports a view to trim holdings at current levels.

The post Buy, hold, sell: Weebit Nano, Metals X, Pro Medicus shares appeared first on The Motley Fool Australia.

More reading

• Up 149% in a year, why this surging ASX 300 tech stock is still a good buy today
• Up 75%, are Pro Medicus shares still a good buy now?
• Why WiseTech shares could rocket 100%
• Where to invest $10,000 in ASX 200 shares in July
• Buy, hold, sell: Pro Medicus, Worley, and ResMed shares

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

These pummeled ASX healthcare shares have both endured brutal share price declines over the past year.

CSL Ltd (ASX: CSL) shares started the week down 0.6% to $122.61. Despite rebounding 13% over the past month, they’re still down around 51% over the past 12 months. Cochlear Ltd (ASX: COH) shares slipped 0.4% on Monday to $119.00, leaving them up 4% over the past month but down an even steeper 61% over the past year.

So, are these former market darlings now genuine buying opportunities or value traps?

CSL: Waiting for earnings to recover

For decades, this $59 billion ASX healthcare share earned its reputation as one of the ASX’s highest-quality companies, driven by global leadership in plasma therapies and a long history of consistent earnings growth.

That reputation has taken a hit. A series of earnings downgrades, leadership changes, and around US$5 billion of non-cash impairments tied largely to the CSL Vifor acquisition have weighed heavily on investor sentiment.

The latest disappointment came in May, when management guided FY26 revenue of approximately US$15.2 billion and NPAT of around US$3.1 billion, both below market expectations. The company also flagged another US$5 billion of non-cash impairments across FY26 and FY27.

Despite that, analysts aren’t entirely bearish. According to TradingView data, 10 of the 18 brokers covering CSL now rate the stock as a hold, while the remaining eight have buy or strong buy recommendations. The average price target sits at $138.88, implying around 13% upside.

UBS remains among the bulls with a $158 target price, arguing much of the bad news surrounding Vifor is already reflected in the share price. The most optimistic analysts see gains of around 60% over the next year.

Cochlear: A temporary stumble?

April marked one of the toughest periods in Cochlear’s history.

The hearing implant leader shocked investors after reporting weaker-than-expected demand across developed markets and disruption to shipments caused by conflict in the Middle East.

Management of the ASX healthcare share slashed FY26 underlying profit guidance from $435 million-$460 million to just $290 million-$330 million, triggering a one-day share price collapse of more than 40%.

Yet the company’s competitive position remains largely intact. Cochlear still controls roughly half the global cochlear implant market, underpinned by decades of product innovation, clinical expertise, and strong relationships with surgeons worldwide.

Its long-term growth opportunity also remains compelling. More than six million people in developed markets are estimated to be eligible for cochlear implants, but only around 3% have received one.

Broker sentiment is cautious. Hold remains the most common TradingView recommendation, with an average target price of $127.14, implying roughly 7% upside.

However, six analysts still rate the shares as a buy or strong buy, with the highest target suggesting upside of around 43%. Two analysts recommend selling, with the lowest target price implying almost 16% downside.

Foolish takeaway

Both ASX healthcare shares remain global leaders with durable competitive advantages, but they are also working through company-specific challenges that have dented investor confidence.

For long-term investors, the sharp share price falls may present an opportunity. However, neither company has yet fully restored market confidence, meaning patience may be required before either regains its former market-leading status.

The post Down 50%+: Are these ASX healthcare shares finally worth buying? appeared first on The Motley Fool Australia.

More reading

• Could CSL shares double from here? Here’s what the experts think
• Here’s why I’d buy and hold CSL and Cochlear shares for 10 years
• Here’s what brokers tip for CSL shares over the next 12 months
• How have CSL shares performed over 10 years?
• Cochlear shares have bounced 16%. Should you buy, hold, or sell now?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.